Rezolute, Inc. (RZLT) — 10-K Filings
All 10-K filings from Rezolute, Inc.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Rezolute's Ersodetug Nears Key Data Readouts for Hyperinsulinism
— Sep 17, 2025 Risk: high
Rezolute, Inc. (RZLT) is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). Their lead asset, ersodetug, an intr -
Rezolute, Inc. Files 2024 Annual Report
— Sep 19, 2024 Risk: medium
Rezolute, Inc. filed its 10-K for the fiscal year ending June 30, 2024, reporting financial results and business operations. The company, formerly known as Antr
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX